Tuesday, July 14, 2020

electroCore (ECOR)

gammaCore Becomes the 1st Approved Medical Device to Treat Coronavirus-related Breathing Difficulty

electrocore Inc is a commercial-stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology and rheumatology. Its product gammaCore is FDA-cleared for the acute treatment of pain associated with migraine and episodic cluster headache in adults.

Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

gammaCore to treat asthma in coronavirus infected patients. The U.S. Food and Drug Administration (FDA) authorized the use of gammaCore for the treatment of asthma exacerbations in known or suspected COVID-19 patients. The shares of gammaCore gained over 100% value upon the emergency use authorization (EUA) news, which was announced yesterday.

gammaCore was shown to improve asthma. The non-invasive vagus nerve stimulation (nVNS) device, gammaCore, showed relief in patients who are experiencing asthma-related breathing difficulty in prior pilot studies. The EUA was granted based on data from two prospective studies, that showed ...

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report.  NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision.